Blu Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 09-12-2024
- Paid Up Capital ₹ 0.10 M
as on 09-12-2024
- Company Age 5 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -47.10%
(FY 2022)
- Profit -275.48%
(FY 2022)
- Ebitda -275.48%
(FY 2022)
- Net Worth -229.93%
(FY 2022)
- Total Assets -57.11%
(FY 2022)
About Blu Pharmaceutical
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Chirag Goyal and Ram Singh serve as directors at the Company.
- CIN/LLPIN
U24299HR2019PTC079650
- Company No.
079650
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Apr 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Faridabad, Haryana, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Blu Pharmaceutical Private Limited offer?
Blu Pharmaceutical Private Limited offers a wide range of products and services, including Medical Laboratory Instruments, Rapid Test Kit, Infusion Syringes & Supplies, Medical Tubes, Corona Test Kit, Urological & Obstetrics Instruments, Urinary Catheter, Forceps & Graspers, Surgical Clamps, Disposable Cannulas.
Who are the key members and board of directors at Blu Pharmaceutical?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chirag Goyal  | Director | 09-Sep-2023 | Current |
| Ram Singh | Director | 09-Apr-2019 | Current |
Financial Performance of Blu Pharmaceutical.
Blu Pharmaceutical Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 47.1% decrease. The company also saw a substantial fall in profitability, with a 275.48% decrease in profit. The company's net worth observed a substantial decline by a decrease of 229.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Blu Pharmaceutical?
Unlock access to Blu Pharmaceutical's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Blu Pharmaceutical?
Unlock and access historical data on people associated with Blu Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Blu Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Blu Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
